Viking Therapeutics VKTX reported a third-quarter 2025 lack of 81 cents per share, wider than the Zacks Consensus Estimate of a lack of 70 cents. The corporate had incurred a lack of 22 cents per share within the year-ago quarter.
At present, Viking Therapeutics doesn’t have any accepted merchandise in its portfolio. Therefore, it has but to generate revenues.
Extra on VKTX’s Q3 Earnings
Analysis and improvement (R&D) bills amounted to $90.0 million in contrast with $22.8 million incurred within the year-ago interval. This important improve was primarily pushed by greater prices related to scientific research and manufacturing for the corporate’s drug candidates, in addition to elevated employee-related bills.
Basic and administrative bills amounted to $8.6 million, down practically 38% 12 months over 12 months, primarily resulting from decrease prices on authorized and patent companies in addition to stock-related compensation bills.
Shares of VKTX had been down in after-market buying and selling yesterday, possible resulting from a wider-than-expected loss on greater working bills incurred within the quarter.
12 months thus far, the inventory has misplaced 22% towards the business’s practically 11% development.
Picture Supply: Zacks Funding Analysis
As of Sept. 30, 2025, Viking Therapeutics had money, money equivalents and short-term investments value $715 million in contrast with $808 million as of June 30, 2025.
VKTX’s Pipeline Updates
Viking Therapeutics is without doubt one of the few biotech shares that has proven immense potential within the weight problems house. It’s creating VK2735, an investigational novel twin GLP-1 and GIP receptor agonist, in numerous scientific research as oral and subcutaneous (SC) variations for treating weight problems.
In June, Viking Therapeutics began a late-stage program evaluating the SC formulation of VK2735 for adults with weight problems. This program consists of two part III research — VANQUISH-1 and VANQUISH-2. Whereas the VANQUISH-1 examine is enrolling overweight adults with a minimum of one weight-related co-morbid situation and with out kind II diabetes (T2D), the VANQUISH-2 examine will enroll overweight or obese adults with T2D. Viking Therapeutics targets finishing enrolment within the VANQUISH-1 examine earlier than year-end, whereas the identical for VANQUISH-2 is predicted within the first quarter of 2026.
Viking Therapeutics additionally just lately reported top-line outcomes from a mid-stage examine evaluating the oral model of VK2735. Although sufferers on the best drug dose misplaced as much as 12.2% of their physique weight after 13 weeks of each day dosing in contrast with 1.3% within the placebo group, a major variety of sufferers dropped out of the examine resulting from opposed results. Regardless of the blended outcomes, Viking Therapeutics nonetheless maintains the drug’s security and tolerability profile. The corporate plans to fulfill with the FDA earlier than this 12 months’s finish to debate the subsequent steps for oral VK2735.
Earlier this week, Viking Therapeutics began a brand new upkeep dosing examine on VK2735. This examine will discover a number of regimens — month-to-month SC, weekly oral and each day oral dosing — to test whether or not the preliminary weight reduction achieved following weekly SC dosing might be sustained. Outcomes from this examine are anticipated in mid-2026.
The corporate now plans to file an investigational new drug (IND) utility with the FDA within the first quarter of 2026 to advance an internally developed amylin agonist program to scientific improvement for treating weight problems. This marks a delay from the beforehand introduced goal of submitting the IND earlier than the top of 2025.
VKTX’s Zacks Rank
Viking Therapeutics at the moment has a Zacks Rank #4 (Promote).
Viking Therapeutics, Inc. Worth
Viking Therapeutics, Inc. worth | Viking Therapeutics, Inc. Quote
Our Key Picks Amongst Biotech Shares
Some better-ranked shares from the sector are Alkermes ALKS, Werewolf Therapeutics HOWL and Alnylam Prescribed drugs ALNY. Whereas ALKS and HOWL every sport a Zacks Rank #1 (Sturdy Purchase) at current, ALNY carries a Zacks Rank #2 (Purchase). You may see the whole listing of immediately’s Zacks #1 Rank shares right here.
EPS estimates for Alkermes’ 2025 have elevated from $1.81 to $1.84, whereas these for 2026 have risen from $1.69 to $1.70 previously 60 days. ALKS inventory has gained 8% 12 months thus far.
Alkermes’ earnings beat estimates in two of the trailing 4 quarters and missed the mark on the opposite two events, delivering a median adverse shock of 1.19%.
Up to now 60 days, loss per share estimates for Werewolf Therapeutics’ 2025 have improved from $1.90 to $1.61. Loss per share estimates for 2026 have narrowed from $1.63 to $1.36 throughout the identical interval. HOWL inventory has gained over 7% 12 months thus far.
Werewolf earnings beat estimates in three of the trailing 4 quarters however missed the mark as soon as, delivering a median shock of seven.36%.
Up to now 60 days, Alnylam’s EPS estimates for 2025 have risen from $3.62 to $4.23. Throughout the identical timeframe, estimates for 2026 EPS have elevated from $9.23 to $10.28. ALNY inventory has soared practically 98% to date this 12 months.
Alnylam’s earnings beat estimates in three of the trailing 4 quarters and met the mark as soon as, delivering a median shock of 348.36%.
Radical New Expertise May Hand Buyers Big Positive aspects
Quantum Computing is the subsequent technological revolution, and it might be much more superior than AI.
Whereas some believed the know-how was years away, it’s already current and shifting quick. Massive hyperscalers, similar to Microsoft, Google, Amazon, Oracle, and even Meta and Tesla, are scrambling to combine quantum computing into their infrastructure.
Senior Inventory Strategist Kevin Cook dinner reveals 7 rigorously chosen shares poised to dominate the quantum computing panorama in his report, Past AI: The Quantum Leap in Computing Energy.
Kevin was among the many early consultants who acknowledged NVIDIA’s huge potential again in 2016. Now, he has keyed in on what might be “the subsequent massive factor” in quantum computing supremacy. At this time, you may have a uncommon likelihood to place your portfolio on the forefront of this chance.
See High Quantum Shares Now >>
Alnylam Prescribed drugs, Inc. (ALNY) : Free Inventory Evaluation Report
Alkermes plc (ALKS) : Free Inventory Evaluation Report
Viking Therapeutics, Inc. (VKTX) : Free Inventory Evaluation Report
Werewolf Therapeutics, Inc. (HOWL) : Free Inventory Evaluation Report
This text initially printed on Zacks Funding Analysis (zacks.com).
The views and opinions expressed herein are the views and opinions of the creator and don’t essentially replicate these of Nasdaq, Inc.
